Почетна › Множен миелом › Северна Каролина › Durham
Клинички испитувања за Множен миелом во Durham, NC
37 студии за Множен миелом бараат учесници на локации во и околу Durham (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.
Официјален текст на студијата (англиски)
Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Се регрутираФаза 3
- Research Site, Chapel Hill · на 10 милји
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Се регрутираФаза 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · на 10 милји
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Се регрутираФаза 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Се регрутираФаза 2
- Duke University Medical Center, Durham
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Се регрутираФаза 3
- Durham VAMC, Durham
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Се регрутираФаза 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · на 10 милји
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Се регрутираФаза 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · на 10 милји
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Се регрутираФаза 3
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Се регрутираФаза 2
- University of North Carolina Medical Center, Chapel Hill · на 10 милји
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Се регрутираФаза 1/2
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · на 10 милји
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Се регрутираФаза 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Се регрутираФаза 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · на 13 милји
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Се регрутираФаза 1/2
- GSK Investigational Site, Chapel Hill · на 10 милји
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Се регрутираФаза 1
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Се регрутираФаза 1/2
- Research Site, Durham
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Се регрутира
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · на 10 милји
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Се регрутираФаза 3
- Research Site, Durham
- Research Site, Chapel Hill · на 10 милји
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Се регрутираФаза 1
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Се регрутираФаза 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · на 10 милји
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Се регрутираФаза 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · на 10 милји
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Се регрутираФаза 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Се регрутираФаза 1
- University of North Carolina /ID# 251203, Chapel Hill · на 10 милји
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Се регрутираФаза 1
- University of North Carolina at Chapel Hill, Chapel Hill · на 10 милји
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Се регрутираФаза 2
- University of North Carolina (Data Collection Only), Chapel Hill · на 10 милји
Registry of Older Patients With Cancer
Се регрутираНабљудувачка студија
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · на 10 милји
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Се регрутираФаза 3
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Се регрутираФаза 2
- University of North Carolina, Chapel Hill · на 10 милји
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
Се регрутираФаза 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · на 10 милји
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Се регрутираФаза 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · на 10 милји
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Се регрутираФаза 1/2
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Се регрутираФаза 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · на 13 милји
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Се регрутираФаза 1
- University of North Carolina, Chapel Hill · на 10 милји
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Се регрутираФаза 1
- University of North Carolina, Chapel Hill · на 10 милји
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Се регрутираФаза 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · на 10 милји
Registry for Adults With Plasma Cell Disorders (PCD's)
Се регрутираНабљудувачка студија
- North Carolina Cancer Hospital, Chapel Hill · на 10 милји
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Се регрутираНабљудувачка студија
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · на 10 милји
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Се регрутираФаза 1
- Duke University Health System (DUHS), Durham
Испитувања за Множен миелом во други градови
- New York City, NY60 студии
- Boston, MA42 студии
- Atlanta, GA42 студии
- Houston, TX38 студии
- Nashville, TN32 студии
- Denver, CO27 студии
- Rochester, MN24 студии
- St. Louis, MO24 студии
- Columbus, OH24 студии
- Baldwin Park, CA23 студии
- Edison, NJ22 студии
- Chicago, IL22 студии
Други студии во Durham
- Рак на дојка64 студии
- Рак (сите типови)58 студии
- Рак на бели дробови со не-мали клетки39 студии
- Акутна миелоидна леукемија33 студии
- Метастатски карцином33 студии
- Рак на простата32 студии
- Рак на бели дробови32 студии
- Колоректален карцином28 студии
- Карцином на јајниците27 студии
- Хронична лимфоцитна леукемија27 студии
- Срцева слабост26 студии
- Карцином на панкреасот24 студии
Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.